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We described the characteristics in a referred cohort of type II
diabetic patients in the Developing Education on
Microalbuminuria for Awareness of renal and cardiovascular
risk in Diabetes study evaluating the global prevalence and
determinants of microalbuminuria (MA). A cross-sectional
study evaluating 32 208 type II diabetic patients without
known albuminuria from 33 countries was performed.
Overall, 8057 patients were excluded, either because of prior
known proteinuria or non-diabetic nephropathy (3670), or
because of invalid urine collections (4387). One single
random urinary albumin/creatinine ratio was obtained in
24 151 patients (75%). The overall global prevalence of
normo-, micro-, and macroalbuminuria was 51, 39, and 10%,
respectively. The Asian and Hispanic patients had the highest
prevalence of a raised urinary albumin/creatinine ratio (55%)
and Caucasians the lowest (40.6), Po0.0001. HbA1c, systolic
blood pressure (BP), ethnicity, retinopathy, duration of
diabetes, kidney function, body height, and smoking were all
independent risk factors of MA, Po0.0001. Estimated
glomerular filtration rate was below 60 ml/min/1.73 m2 in
22% of the 11 573 patients with available data. Systolic BP
below 130 mmHg was found in 33 and 43% had an HbA1c
below 7%. The frequency of patients receiving aspirin was
32%, statins 29%, and BP-lowering therapy 63%. A high
prevalence globally of MA and reduced kidney function, both
conditions associated with enhanced renal and
cardiovascular risk, was detected in type II diabetic patients
without prior known nephropathy. Early detection,
monitoring of vascular complications, and more aggressive
multifactorial treatment aiming at renal and vascular
protection are urgently needed.
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In 1969, Keen et al.1 first described microalbuminuria (MA)
(an abnormal increase in the rate of urinary excretion of
albumin to between 30 and 300 mg/24 h) in patients with
diabetes mellitus. Five years later, Parving et al.2 demons-
trated that MA was associated with essential hypertension in
non-diabetic subjects. In the early 1980s, several longitudinal
studies in type I and type II diabetes documented that MA
was a powerful independent risk factor for developing
diabetic nephropathy.3–5 Later, several prospective epidemio-
logic studies demonstrated that MA is an important risk
factor for cardiovascular disease (CVD) in type II diabetic
patients. A meta-analysis of these studies showed that the
presence of MA doubles the risk of cardiovascular morbidity
or mortality.6 Observational studies in non-diabetic subjects
have revealed that MA is also an independent powerful risk
factor for fatal and non-fatal vascular events and all-cause
mortality.7,8 Conversely, a prespecified analysis revealed that
reduction in urinary albumin excretion translates to reduc-
tion in cardiovascular events in hypertensive patients treated
with blockade of the renin-angiotensin system.9 Intervention
studies aiming at improved glycemic control and blockade
of renin-angiotensin system have both demonstrated that
the development of diabetic nephropathy can be postponed
in type II diabetic patients with normoalbuminuria
and/or MA.10–12 Despite the knowledge gained in relation
to early identification and intervention in high-risk type II
diabetic patients, diabetic nephropathy is still the leading
cause of end-stage renal disease in most countries of the
world.13
In 2003, the International Diabetes Federation and the
International Society of Nephrology developed the theme,
‘Diabetes could cost you your kidneys: Act Now!’ We acted in
collaboration with these two organizations and Bristol-Myers
Squibb and Sanofi-Aventis to create a study on Developing
Education on Microalbuminuria for Awareness of renal and
cardiovascular risk in Diabetes (DEMAND). This cross-
sectional global study describes the prevalence and risk
factors for MA, and implementation of cardiovascular
protective treatment in normo- and hypertensive type II
diabetic patients without known proteinuria and/or
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non-diabetic kidney disease. The study is clinic/medical
center based and not population based.
RESULTS
The characteristics of the patients according to ethnic
groups are shown in Table 1. Overall, the mean age was 61
years, the gender distribution 50/50, mean duration of
diabetes 7.6 years, HbA1c 7.5% (but data missing in 37%
of the patients), diabetic retinopathy present in 12%, 23% of
the patients had a prior history of any CVD, and 26%
had a history of smoking. Table 1 shows that the Hispanic
group differs from the other groups by a lower male
participation, higher HbA1c, family history of diabetes and
CVD, presence of retinopathy, whereas prevalence of
hypertension was lower. The Caucasian group had the
lowest HbA1c but the highest frequency of hyperlipidemia
and positive history of CVD. The African group was
characterized by being youngest with the shortest known
diabetes duration.
Diabetes treatments received by our patients are presented
in Table 2. Only 9% received diet alone, whereas the
remaining received oral hypoglycemic drugs and/or insulin.
The Caucasian group was characterized by the highest
frequency of antihypertensive treatment, number of anti-
hypertensive agents, use of angiotensin-converting enzyme
inhibitor or angiotensin receptor blocker, lipid-lowering
agents, and anticoagulant/platelet agents (Table 2). Among
the 24 151 patients in our final data set, 19 574 (81%) had
systolic blood pressure (BP) X130 mmHg and/or diastolic
BP X80 mmHg; 859 (3.6%) had missing data about
antihypertensive use. There is little difference in the fraction
of patients not on antihypertensives among normo-, micro-,
and macroalbuminuric patients (34, 29, and 30%, respec-
tively. Antihypertensive drugs were prescribed to 63% of the
patients who on average received 1.7 agents daily. Drugs
blocking the RAS, followed by diuretics and calcium-channel
blockers were most commonly used. The number of BP-
lowering drugs increased with the level of systolic BP. The
percentage of patients not receiving antihypertensive medica-
tion dropped from approximately 35% at a systolic BP level
of 140 mmHg to approximately 10% at a systolic BP equal to
200 mmHg.
Table 1 | Characteristics of patients with type II diabetes by ethnic group
Caucasian African Asian Other Hispanic Missinga Total P-value
Demographic characteristics
Number 9441 (39%) 490 (2%) 9111 (38%) 661 (2.7%) 1180 (4.9%) 3259 (13%) 24 151 (100%)
Age (years) 63.2711.2 54.4710.7 59.9711.6 60.4712.2 57.1711.8 63.1711.6 61.4711.7 o0.0001
Age (% missing) 202 (2.1) 6 (1) 97 (1) 16 (2.4) 28 (2.4) 238 (7.3) 587 (0.24) o0.0001
Gender
Male 4730 (50%) 253 (52%) 4.498 (49%) 357 (54%) 436 (37%) 1530 (47%) 11 804 (49%) o0.0001
Female 4604 (49%) 235 (48%) 4572 (50%) 300 (45%) 745 (63%) 1643 (50%) 12 099 (50%)
Missing 107 (1%) 2 (0.4%) 41 (0.5%) 4 (0.6%) 8 (0.7%) 86 (2.6%) 248 (0.1%)
Region
Europe 5792 (61%) 12 (2.4%) 94 (1%) 174 (26%) 36 (3%) 2216 (68%) 8324 (34%) o0.0001
Asia 7 (0%) 2 (0.5%) 7844 (86%) 17 (2.6%) 0 (0%) 716 (22%) 8586 (36%)
Africa 497 (5%) 359 (73%) 342 (3.8%) 62 (9.4%) 0 (0%) 71 (2.2%) 1331 (5.5%)
North America 2095 (22%) 93 (19%) 325 (3.6%) 123 (19%) 922 (78%) 100 (3.1%) 3658 (15%)
Central/South America 223 (2.4%) 22 (4.5%) 9 (0.1%) 189 (29%) 231 (19%) 61 (1.9%) 735 (3%)
Oceania 827 (8.8%) 2 (0.4%) 497 (5.5%) 96 (15%) 0 (0%) 95 (2.9%) 1517 (6.3%)
Clinical characteristics
Height (cm) 166.5710.0 165.579.2 161.878.8 163.279.8 158.379.5 165.179.9 164.079.8 o0.0001
Height (% missing) 132 (1.4) 24 (4.9) 123 (1.4) 11 (1.7) 13 (1.1) 121 (3.7) 424 (1.8) o0.0001
BMI (kg/cm2) 30.075.6 30.775.7 24.974.1 28.675.1 28.574.9 28.475.3 28.875.5 o0.0001
BMI (% missing) 186 (2) 25 (5.1) 148 (1.6) 25 (3.8) 18 (1.5) 146 (4.5) 548 (2.3) o0.0001
Duration of diabetes (years) 7.876.2 6.775.1 7.176.1 7.976.2 8.276.5 8.176.2 7.676.2 o0.0001
Duration of diabetes (% missing) 689 (7.3) 20 (4.1) 746 (8.2) 47 (7.1) 32 (2.7) 233 (7.1) 1767 (7.3) o0.0001
HbA1c (%) 7.271.5 8.272.1 7.871.8 7.871.7 8.271.8 7.571.6 7.571.6 o0.0001
HbA1c (% missing) 2092 (22) 158 (32) 5147 (56) 155 (23) 584 (49) 786 (24) 8922 (37) o0.0001
Medical history
Family history of diabetes 4876 (52%) 311 (63%) 3742 (41%) 383 (58%) 822 (69%) 1537 (47%) 11 671 (48%) o0.0001
Retinopathy 942 (10%) 28 (5.7%) 1304 (14%) 82 (12%) 189 (16%) 398 (12%) 2943 (12%) o0.0001
Diabetic foot 393 (4.2%) 13 (2.7%) 373 (4.1%) 43 (6.5%) 57 (4.8%) 176 (5.4%) 1055 (4.4%) 0.0005
History of hypertension 6442 (68%) 329 (67%) 4873 (53%) 376 (57%) 539 (45%) 2182 (67%) 14 741 (61%) o0.0001
Family history of CVD 3422 (36%) 91 (19%) 1890 (21%) 213 (32%) 441 (37%) 885 (27%) 6942 (29%) o0.0001
Smoking history 2749 (29%) 114 (23%) 2002 (22%) 187 (28%) 293 (25%) 933 (29%) 6278 (26%) o0.0001
Hyperlipidemia 4702 (50%) 92 (19%) 3372 (37%) 321 (49%) 383 (32%) 1543 (47%) 10 413 (43%) o0.0001
Positive history of any CVD 2843 (30%) 43 (8.8%) 1589 (17%) 113 (17%) 226 (19%) 733 (22%) 5547 (23%) o0.0001
BMI, body mass index; CVD, cardiovascular disease.
aIn this column, data on ethnicity are missing, whereas other data are available.
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Only 37% of our patients received lipid-lowering drugs,
and antiplatelet/anticoagulant agents were applied in a
similar fraction of the patients.
Normoalbuminuria was demonstrated in 51%, MA in
39%, and the remaining 10% had macroalbuminuria
(Table 3). The prevalence of abnormally elevated urinary
albumin excretion was highest in Asian and Hispanic patients
and the Caucasians had the lowest value, Po0.0001. Table 4
shows the odds ratio of micro-/macroalbuminuria, arranged
in such a way that the first variable added is the one that has
most explanatory value, followed by the second most
explanatory. Several of the risk factors are modifiable, for
example, HbA1c, systemic BP, and smoking.
Overall, estimated glomerular filtration rate (eGFR)
averaged 78 ml/min/1.73 m2 and 22% of the patients had
renal insufficiency, that is eGFR o60 ml/min/1.73 m2. The
prevalence of renal insufficiency rose from normo- to micro-
to macroalbuminuria (17, 27.5, and 30.7%, respectively). The
total number of patients with chronic kidney disease was
58%. Conversely, the prevalence of any known CVD was
similar in patients with normo-, micro-, and macroalbumin-
uria (21, 25, and 23%, respectively).
DISCUSSION
Our global cross-sectional study of type II diabetic patients
without previously known proteinuria or kidney disease
Table 2 | Medical treatment in patients with type II diabetes by ethnic group
Caucasian African Asian Other Hispanic Missing Total P-value
Treatment
Glucose lowering o0.0001
Diet alone 1237 (13%) 18 (3.7%) 619 (6.8%) 48 (7.3%) 78 (6.6%) 187 (5.7%) 2187 (9.1%)
Oral hypoglycemic agent 5991 (63%) 314 (64%) 6917 (76%) 446 (67%) 866 (73%) 2361 (72%) 16 895 (70%)
Insulin 1131 (12%) 92 (19%) 709 (7.8%) 77 (12%) 151 (13%) 273 (8.4%) 2433 (10%)
Both 782 (8.3%) 58 (12%) 753 (8.3%) 72 (11%) 62 (5.2%) 340 (10%) 2.067 (8.6%)
Missing 300 (3.2%) 8 (1.6%) 113 (1.2%) 18 (2.7%) 32 (2.7%) 98 (3.0%) 569 (2.4%)
Antihypertensive treatment
On any antihypertensive agent 6825 (72%) 307 (63%) 4691 (51%) 421 (64%) 627 (53%) 2343 (72%) 15 214 (63%) o0.0001
Number of antihypertensive agents 1.870.92 1.870.85 1.570.71 1.670.82 1.470.64 1.870.84 1.770.85 o0.0001
Diuretics 2694 (29%) 157 (32%) 871 (9.6%) 127 (19%) 139 (12%) 928 (28%) 4916 (20%) o0.0001
ACEI 4002 (42%) 179 (37%) 2027 (22%) 235 (36%) 417 (35%) 1277(39%) 8137 (34%) o0.0001
ARB 1606 (17%) 59 (12%) 848 (9.3%) 133 (20% 91 (7.7%) 483 (15%) 3220 (13%) o0.0001
ACEI or ARB 5431 (58%) 234 (48%) 2817 (31%) 360 (54%) 499 (42%) 1729 (53%) 11 070 (46%) o0.0001
Beta blockers 1689 (18%) 38 (7.8%) 848 (9.3%) 61 (9.2%) 83 (7.0%) 604 (19%) 3323 (14%) o0.0001
Calcium-channel blockers 2060 (22%) 99 (20%) 1909 (21%) 103 (16%) 101 (8.5%) 690 (21%) 4962 (21%) o0.0001
Alpha blockers 248 (2.6%) 1 (0.2%) 159 (1.7%) 7 (1.1%) 15 (1.3%) 77 (2.4%) 507 (2.1%) o0.0001
Other antihypertensive agents 248 (2.6%) 8 (1.6%) 399 (4.4%) 16 (2.4%) 9 (7.6%) 78 (2.4%) 758 (3.1%) o0.0001
Lipid-lowering agents
Statin 3731 (40%) 61 (12%) 1646 (18%) 223 (34%) 157 (13%) 1164 (36%) 6982 (29%) o0.0001
Other lipid-lowering agents 643 (6.8%) 13 (2.7%) 989 (11%) 34 (5.1%) 77 (6.5%) 257 (7.9%) 2013 (8.3%) o0.0001
On anticoagulant/antiplatelet agents 4349 (46%) 156 (32%) 2266 (25%) 272 (41%) 400 (34%) 1362 (42%) 8805 (36%) o0.0001
On Aspirin 3708 (39%) 150 (31%) 1986 (22%) 242 (37%) 365 (31%) 1186 (36%) 7637 (32%) o0.0001
On Warfarin 331 (3.5%) 3 (0.6%) 38 (0.4%) 8 (1.2%) 6 (0.5%) 80 (2.5%) 466 (1.9%) o0.0001
On other anticoagulant/antiplatelet agents 402 (4.3%) 7 (1.4%) 283 (3.1%) 28 (4.2%) 38 (3.2%) 124 (3.8%) 882 (3.7%) o0.0001
ACEI, angiotensin-converting enzyme inhibition; ARB, angiotensin receptor blocker.
Table 3 | Albuminuria, kidney function, and arterial blood pressure in patients with type II diabetes by ethnic group
Caucasian African Asian Other Hispanic Missing Total P-value
Laboratory variables
Albuminuria o0.0001
None 5576 (59%) 279 (57%) 4046 (44%) 354 (54%) 545 (46%) 1628 (50%) 12 428 (51%)
Micro 3145 (33%) 177 (36%) 3942 (43%) 258 (39%) 521 (44%) 1325 (41%) 9368 (39%)
Macro 720 (7.6%) 34 (6.9%) 1123 (12%) 49 (7.4%) 123 (10%) 306 (9.4%) 2355 (9.8%)
Log 2 (albumin/creatinine ratio) 4.671.8 4.671.7 5.271.9 4.871.7 5.271.8 4.971.8 4.971.8 o0.0001
Serum creatinine (mg/dl) 0.9870.32 1.0070.38 1.0070.39 0.9770.30 1.0870.98 1.0470.40 1.0070.40 o0.0001
Serum creatinine (% missing) 3642 (39) 275 (56) 5901 (65) 241 (36) 683 (57) 1576 (48) 12 318 (51) o0.0001
MDRD GFR (ml/min) 78724 97.4730.0 79.0727.3 81.4726.3 75.1729.5 74.8725.6 78.2726.0 o0.0001
MDRD GFR (% missing) 3746 (40) 276 (56) 5920 (65) 247 (37) 693 (58) 1696 (52) 12 578 (52) o0.0001
Systolic BP (mmHg) 137.0717 136.2719.3 132.2718.3 133.2717.7 131.0718.9 137.2716.5 134.8717.8 o0.0001
Systolic BP (% missing) 350 (3.7) 38 (7.8) 286 (3.1) 36 (5.4) 30 (2.5) 122 (3.7) 862 (3.6) o0.0001
Diastolic BP (mmHg) 79.879.6 82.9711.7 78.8710.3 79.379.1 80.2710.2 80.379.3 79.679.9 o0.0001
Diastolic BP (% missing) 360 (3.8) 37 (7.6) 297 (3.3) 38 (5.7) 29 (2.4) 124 (3.8) 885 (3.7) o0.0001
BP, blood pressure; GFR, glomerular filtration rate; MDRD, modification of diet in renal disease.
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based on medical records revealed that approximately 50%
had micro- or macroalbuminuria, one-fifth had renal
insufficiency, and 80% had elevated BP. This large clinic/
medical center-based study demonstrates the high burden of
renal disease in Asian and Hispanic subjects with type II
diabetes compared with Caucasians. In addition, several
potentially modifiable risk factors such as glycemic
control, arterial BP, and smoking are associated with the
presence of micro- and macroalbuminuria. Known diabetes
duration is a well-established risk factor for vascular
complications, and consequently our data must be regarded
as rather conservative, as the average known duration was
only 8 years.
Previous studies have established MA as a powerful
independent predictor of microvascular lesions, CVD,
cardiovascular mortality, and kidney disease including end-
stage renal failure in patients with diabetes, hypertensive
subjects, and even in the general population.6–8,14 Our study
shows a clear association of higher levels of albuminuria with
an increased frequency of renal insufficiency, which we
measured, but not of known CVD, of which we obtained only
a history. It is likely that many more of these patients had
asymptomatic CVD. However, patients with congestive heart
failure had increased levels of albuminuria. The apparent
discrepancy between congestive heart failure and CVD may
be a chance finding, or reflects that cerebrovascular and
peripheral arterial disease acts differently from cardiac disease
in relation to micro-/macroalbuminuria.
Our study has several limitations. First, albumin/creati-
nine ratio was determined by a dipstick on the basis of a
single random urine collection. However, the large number of
samples collected and the high frequency with which a single
urine collection showed a diagnostic abnormality should
minimize the uncertainty associated with day-to-day diffe-
rences in urinary albumin excretion. Second, our data do not
permit examination of the generally accepted criterion for
persistent MA, requiring that two out of three determinations
are within the target range. However, other data suggest that
this requirement only will reduce the point prevalence by
one-fifth.15 A third limitation is that our study is not
population based and consequently our sampling frame is
most well defined. Selection bias in relation to the
participating centers and subsequently enrolled diabetic
patients cannot be ruled out. However, it should be
mentioned that our data dealing with the prevalence of
abnormally elevated urinary albumin excretion (55%) in the
Asian subset (N¼ 9111) are comparable with the high
prevalence (58.6%) of micro- or macroalbuminuric observed
in a cross-sectional study of 5549 type 2 diabetic patients
from 10 Asian Countries or regions.16 This study applied
consecutive screening.
Our study confirms and extends previous observations
suggesting a high prevalence of MA in several non-European
groups throughout the world.16,17 In addition, our study
revealed an association between micro-/macroalbuminuria
and several vascular risk factors, for example HbA1c, systolic/
diastolic BP, smoking, and eGFR. Surprisingly, increased
body mass index was not related to the presence of micro-/
macroalbuminuria, which may be because of the high
prevalence of micro-/macroalbuminuria in the Asian popula-
tion who had the lowest body mass index.
Many physicians have difficulties in interpretation of
serum creatinine, and consequently recent nephrology
recommendations suggest that laboratories should provide
GFR estimates as a regular laboratory test using standard
validated prediction equations such as the modification of
diet in renal disease (MDRD) formula.18 Unfortunately,
serum creatinine data were missing in half of our patients,
but in the remaining subjects renal insufficiency was detected
in 22%, increasing from normo- to macroalbuminuria. The
finding of renal insufficiency in 17% of our normoalbumin-
uric patients was surprising, but support and extend data
from Australia.19 The causes of this loss in kidney function
are poorly understood, but some data suggest that the
MDRD formula underestimates the GFR, particularly in
subjects with normal GFR.20 Several recent studies suggest
that reduced eGFR is a powerful independent risk factor of
death, cardiovascular events, and hospitalization.21–24
Furthermore, it should be stressed that there is an substantial
rise in risk of all-cause mortality when eGFR (MDRD
formula) falls below 60 ml/min/1.73 m2 and downwards.23
These findings document that quantification of renal
function seems to provide an index of overall vascular
health, even though the applied MDRD formula may
underestimate GFR.
Type II diabetic patients have a risk of fatal and non-fatal
cardiovascular events that is two to six times that in subjects
without diabetes.6,25,26 Patients with micro- and macroalbumin-
uria suffer the highest risk. This poor outcome is related to
several modifiable risk factors such as hyperglycemia,
hypertension, dyslipoproteinaemia, and increased platelet
aggregability. Randomized double masked trials aiming at
reducing these vascular risk factors in type II diabetes have
demonstrated benefits in relation to large and small vessel
Table 4 | Risk (odds ratio) of micro-/macroalbuminuria in
patients with type II diabetes
Variables Odds ratio 95% CI P-value
HbA1c (per 1%) 1.13 1.11, 1.15 o0.0001
Systolic blood pressure (per 10 mmHg) 1.10 1.08, 1.12 o0.0001
Black vs Caucasian 1.48 1.20, 1.83 0.0002
Asian vs Caucasian 1.77 1.59, 1.97 o0.0001
Hispanic vs Caucasian 1.69 1.47, 1.94 o0.0001
Retinopathy 1.49 1.38, 1.62 o0.0001
Known duration of diabetes (per year) 1.02 1.01, 1.03 o0.0001
Estimated GFR (per 10 ml/min) 0.96 0.95, 0.98 o0.0001
Diabetic foot lesions 1.64 1.45, 1.86 o0.0001
Height (per 5 cm) 0.96 0.94, 0.97 o0.0001
Congestive heart failure 1.56 1.32, 1.84 o0.0001
Diastolic blood pressure (per 10 mmHg) 1.10 1.07, 1.14 o0.0001
Smoking 1.15 1.08, 1.22 o0.0001
Age (per 10 years) 1.04 1.01, 1.07 0.0034
CI, confidence interval; GFR, glomerular filtration rate.
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disease.26–29 Whereas the previous studies investigated the
effect of intensified intervention involving a single vascular
risk factor, the Steno-2 study evaluated the effect on CVD of
an intensified, targeted, multifactorial intervention aimed at
several modifiable risk factors in patients with type II
diabetes and MA.30,31 The Steno-2 study revealed that
multifactorial intervention reduced the risk of cardiovascular
and microvascular events by about 50%.
The average HbA1c in DEMAND is lower than that
reported in the intensified arm of the United Kingdom
Prospective Diabetes Study (UKPDS) and Steno-2 study.
However, values were missing in 37% of our patients, and
patients with missing HbA1c values had an odds ratio of 1.25
for higher levels of albuminuria, clearly suggesting bias
against higher values of HbA1c. In addition, standardization
of HbA1c assay was not available.
Several guidelines suggest a target BP below 130/80 mmHg
in type II diabetic patients and even lower in patients
with micro-/macroalbuminuria.32 The DEMAND study
revealed that the majority of patients had BP above the
recommended levels, and one-third of these patients did not
receive BP-lowering therapy, despite the well-documented
benefit on large and small vessel disease.32 The majority of
the treated patients received agents blocking the renin–
angiotensin system. Angiotensin-conveting enzyme inhibi-
tion was most commonly used in all groups. As expected,
the Asian group had the lowest utility of angiotensin-
converting enzyme inhibitors, probably owing to their
enhanced risk of coughing. Despite this side effect, the
frequency of angiotensin receptor blockers was still low
(9.3%) in the Asian group. Increased cost may partly explain
the finding.
Several statin trials have demonstrated a beneficial effect
on cardiovascular events, including ischemic stroke, in
patients with type II diabetes without high levels of low-
density lipoprotein-cholesterol.28,29,33 Furthermore, these
drugs are safe. Consequently, there is a strong argument that
all subjects with type II diabetes warrant statin treatment.34
Lipid-lowering therapy was only recorded in approximately
one-third of the DEMAND patients, despite these patients
having a high frequency of several conventional cardiovas-
cular risk factors including micro- and macroalbuminuria.
Only one-third of our patients received antiplatelet agents,
despite a large meta-analysis clearly indicating a cardiovas-
cular benefit in diabetes.35
The main strengths of our cross-sectional study included a
large, multiracial referred cohort of type II diabetic subjects
with validated identification of predefined primary and
secondary end points. However, several limitations should
be noted. First, we obtained only a single determination of
urinary albumin/creatinine ratio and arterial BP. Second, bias
was documented in relation to some of the missing variables,
for example HbA1c and eGFR. Third, dosing of the different
drugs was not obtained. Finally, serum creatinine assays were
not calibrated to national and preferable international
reference standards.
Conclusion
A high prevalence globally of micro- and macroalbuminuria
and reduced kidney function, conditions associated with
enhanced renal and cardiovascular risk, was detected in type
II diabetic patients without prior known nephropathy. Early
detection, monitoring of vascular complication, and more
aggressive multifactorial treatment aiming at renal and
vascular protection are urgently needed.
MATERIALS AND METHODS
Patients
Total number of patients was 32 208. Eligible patients were normo-
or hypertensive women and men between 18 and 80 years, with type
II diabetes mellitus (World Health Organization criteria) without
prior known proteinuria and/or non-diabetic kidney disease.
A history of kidney disease and/or proteinuria was recorded in
3670 patients leaving 28 538 appropriate patients. Invalid urine
collections owing to fever, menstruation, pyuria, missing urine
creatinine, or urine too dilute (see below) were observed in 4384.
Three patients whose nationality and region were missing were also
deleted. One single random albumin/creatinine ratio was obtained
in 24 151 patients (75%). The DEMAND study is a multinational
cross-sectional clinic/center-based study designed to evaluate the
prevalence and determinants of micro- and macroalbuminuria in
type II diabetic patients by random screening at each participating
center during the interval from end of June to end of September
2003. The goal was to enroll 10 type II diabetic patients per center.
The study was mainly performed in primary care settings. The study
was endorsed and the center selected by local diabetes associations
in collaboration with Bristol-Myers Squibb and Sanofi-Aventis. A
total of 3137 physicians in 33 different countries in Asia, Europe,
Central America, South America, North America, Africa, and
Oceania participated. The study protocol was approved by the
ethical committee of each clinic and all patients gave written
informed consent. The study was overseen by a steering committee
(present authors, except LGH), which contained two non-voting
members who were employed by the two sponsoring pharmaceutical
companies (Bristol-Myers Squibb and Sanofi-Aventis). The steering
committee oversaw the study design, the conduct of the investiga-
tion, and the management, and analyses of the data. A writing
subcommittee of the steering committee prepared this report (HHP,
LGH).
Investigations
All participating general practitioners, physicians and nurses
received the full study protocol and were instructed in performing
the urinary albumin/creatinine test (single determination), and BP
measurement with an appropriate cuff after approximately 10 min
rest in the sitting position (single recording). Furthermore,
demographic (age, gender, ethnicity, and region), clinical characte-
ristics (height, body mass index, known diabetes duration, HbA1c,
and serum creatinine), medical history (family history of diabetes/
hypertension/CVD, retinopathy, diabetic foot lesion, history of any
CVD, smoking, and hyperlipidemia), and simultaneous treatments
(glucose lowering, antihypertensive agents, lipid-lowering drugs and
antiplatelet/anticoagulant agents) on each patient were recorded on
a single page clinical report form . Presence of CVD, that is coronary
artery disease, myocardial infarction, left ventricular hypertrophy,
congestive heart failure, stroke, transient ischemic attack, or
peripheral vascular disease, was based on medical records and
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information obtained during the interview. Standardized definitions
of the different CVDs were not applied. Presence of hyperlipidemia
was based on objective measurements as stated in the medical
records. Presence of arterial hypertension was based on medical
history of patient receiving BP-lowering therapy. A single random
urine albumin/creatinine ratio was measured using Bayer reagent
strip Multistixs 10SG. According to this semiquantitative strip test,
normoalbuminuria is defined as albumin-to-creatinine ratio
o30 mg/g, MA 30–299 mg/g, and macroalbuminuria X300 mg/g.
According to the manufacturer, the Multistixs 10SG test has a
sensitivity of 84% and specificity of 91% for the albumin-
to-creatinine ratio. Urine samples with concentrations of creatinine
p10 mg/dl were discarded as too dilute, as prespecified in the
protocol.
We used the MDRD 4 variable formula (serum creatinine level,
age, sex, and African race or not) to estimate the GFR (ml/min/
1.73 m2).18 The stages of chronic kidney disease were defined
according to the American National Kidney Foundation:18 stage 1,
eGFRX90; stage 2, eGFR 60–89; stage 3, eGFR 30–59; stage 4, 15–29;
and stage 5, eGFRo15 or dialysis. Patients belonging to stage 1 and
2 need to have structural or functional abnormalities of the kidney,
for example, micro-/ macroalbuminuria, to be classified as having
chronic kidney disease. A eGFR o60 ml/min/1.73 m2 is defined as
renal insufficiency.
Statistical analysis
Univariate comparisons of the impact of independent variables
on the average levels of continuous and categorical dependent
variables were made using one-way analysis of variance and the w2
statistic, respectively. A minimal multivariate model predicting the
level of albuminuria (normal, micro-, or macroalbuminuria) was
constructed using ‘proportional odds’ ordinal logistic models as
realized by the function lrm for S.36 Parallel models predicting the
albumin/creatinine ratio (log transformed) as a continuous variable
were built using ordinary linear regression models and gave
comparable results. To build these models, independent variables
were added to the model in the order in which they increased the
total likelihood of the model, taken as a measure of explanatory
power, until no further additions significantly (Po0.05) improved
the likelihood, using the likelihood ratio test. All data management
was performed using SAS for Windows version 9.0 (SAS Institute,
Cary, NC, USA) and all analyses were performed using S-Plus
version 6.2 for Windows (Insightful Corp., Seattle, WA, USA) by LG
Hunsicker.
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